Biogen Inc
NASDAQ:BIIB

  • LAST PRICE
    174.0000
  • TODAY'S CHANGE (%)
    -7.1800 (-3.9629%)
  • Bid / Lots
    174.5000/ 8
  • Ask / Lots
    175.0000/ 1
  • Open / Previous Close
    178.1100 / 181.1800
  • Day Range
    174.0000
    179.4751
  • 52 Week Range
    173.8750
    268.2950
  • Volume
    1,755,618

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
BIIB
Biogen Inc
26.4B
15.7x
-18.14%
ICLR
ICON PLC
18.8B
24.7x
+4.68%
MRNA
Moderna Inc
21.0B
-3.5x
---
GRFS
Grifols SA
7.0B
36.1x
---
BNTX
Biontech SE
27.1B
-49.6x
---
IQV
IQVIA Holdings Inc
39.4B
27.0x
+46.62%
As of 2024-11-01

Company Information

Biogen Inc. is a global biopharmaceutical company focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. It also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. It commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

Contact Information

Headquarters
225 Binney StreetCAMBRIDGE, MA, United States 02142
Phone
781-464-2000
Fax
302-636-5454

Executives

Independent Chairman of the Board
Caroline Dorsa
President, Chief Executive Officer, Director
Christopher Viehbacher
Chief Financial Officer, Executive Vice President
Michael McDonnell
Chief Human Resource Officer, Executive Vice President
Ginger Gregory
Executive Vice President, Chief Legal Officer
Susan Alexander

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$25.3B
Revenue (TTM)
$9.6B
Shares Outstanding
145.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.06
EPS
$11.07
Book Value
$102.14
P/E Ratio
15.7x
Price/Sales (TTM)
2.6
Price/Cash Flow (TTM)
11.2x
Operating Margin
22.56%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.